Advertisement

Prognostic Value of Primary Tumor Sidedness for Unresectable Stage IV Colorectal Cancer: A Retrospective Study

  • Dai ShidaEmail author
  • Taro Tanabe
  • Narikazu Boku
  • Atsuo Takashima
  • Takefumi Yoshida
  • Shunsuke Tsukamoto
  • Yukihide Kanemitsu
Colorectal Cancer
  • 61 Downloads

Abstract

Background

When treated with molecular targeted agents, patients with unresectable colorectal cancer with right-sided tumors have poorer prognoses than those with left-sided tumors. While primary tumor sidedness may have prognostic value, the prognostic value of tumor sidedness in chemotherapy regimens without targeted therapy is unclear.

Methods

Our study population comprised 678 consecutive patients with unresectable stage IV colorectal cancer who received systemic chemotherapy at the National Cancer Center Hospital in Japan from 1999 to 2015. Patients were stratified by treatment subgroup (with or without molecular targeted agents and with or without palliative primary tumor resection), and relationships between overall survival (OS) and primary tumor sidedness were evaluated. Multivariate analyses were also performed.

Results

Overall, 193 (28%) tumors were right-sided (cecum to transverse colon) and 485 (72%) were left-sided (splenic flexure to rectum). In the overall population, median survival time was 16.4 months for those with right-sided tumors and 23.4 months for those with left-sided tumors (p < 0.01). Regardless of the use or non-use of targeted agents and performance or non-performance of palliative resection of the primary tumor, those with right-sided tumors showed significantly poorer prognosis than those with left-sided tumors, in all categories. Multivariate analyses showed right-sided tumors to be associated with shorter OS compared with left-sided tumors (hazard ratio 1.26, 95% confidence interval 1.03–1.53; p =0.024).

Conclusion

Unresectable stage IV right-sided colorectal tumors were associated with shorter OS compared with left-sided tumors, regardless of treatment strategy. Primary tumor sidedness may be an independent prognostic factor.

Notes

Acknowledgment

The authors thank Moriya M., Shimada Y., Akasu T., Fujita S., Yamamoto S., Hamaguchi T., and Ochiai H., all of whom were former staff members in our divisions. The authors also thank all colleagues and nurses involved in patient care. The present study is not based on any previous communication to a society or meeting.

Commercial Interests

The authors have no commercial interests to report.

Conflict of interest

Dai Shida, Taro Tanabe, Narikazu Boku, Atsuo Takashima, Takefumi Yoshida, Shunsuke Tsukamoto, and Yukihide Kanemitsu have no conflict of interest to report.

Supplementary material

10434_2019_7209_MOESM1_ESM.docx (20 kb)
Supplementary material 1 (DOCX 19 kb)

References

  1. 1.
    UICC. TNM classification of malignant tumours. 8th ed. New York: Wiley; 2017.Google Scholar
  2. 2.
    Allegra CJ, Jessup JM, Somerfield MR, et al. American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091–6.CrossRefGoogle Scholar
  3. 3.
    Sinicrope FA, Shi Q, Smyrk TC, et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2015;148(1):88–99.CrossRefGoogle Scholar
  4. 4.
    Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012;18(23):6531–41.CrossRefGoogle Scholar
  5. 5.
    Lee MS, Menter DG, Kopetz S. Right versus left colon cancer biology: integrating the consensus molecular subtypes. J Natl Compr Cancer Netw. 2017;15(3):411–9.CrossRefGoogle Scholar
  6. 6.
    Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713–29.CrossRefGoogle Scholar
  7. 7.
    Tejpar S, Stintzing S, Ciardiello F, et al. prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: Retrospective analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol. Epub 10 Oct 2016.  https://doi.org/10.1001/jamaoncol.2016.3797.
  8. 8.
    Loupakis F, Yang D, Yau L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107(3): pii: dju427.Google Scholar
  9. 9.
    Shida D, Tsukamoto S, Ochiai H, Kanemitsu Y. long-term outcomes after R0 resection of synchronous peritoneal metastasis from colorectal cancer without cytoreductive surgery or hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2018;25(1):173–8.CrossRefGoogle Scholar
  10. 10.
    Shida D, Yoshida T, Tanabe T, Tsukamoto S, Ochiai H, Kanemitsu Y. Prognostic impact of R0 resection and targeted therapy for colorectal cancer with synchronous peritoneal metastasis. Ann Surg Oncol. 2018;25(6):1646–53.CrossRefGoogle Scholar
  11. 11.
    Cartwright TH, Yim YM, Yu E, Chung H, Halm M, Forsyth M. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology. Clin Colorectal Cancer. 2012;11(4):238–46.CrossRefGoogle Scholar
  12. 12.
    Shida D, Hamaguchi T, Ochiai H, et al. Prognostic impact of palliative primary tumor resection for unresectable stage 4 colorectal cancer: using a propensity score analysis. Ann Surg Oncol. 2016;23(11):3602–8.CrossRefGoogle Scholar
  13. 13.
    Shida D, Ochiai H, Tsukamoto S, Kanemitsu Y. Long-term outcomes of laparoscopic versus open D3 dissection for stage II/III colon cancer: results of propensity score analyses. Eur J Surg Oncol. 2018;44(7):1025–30.CrossRefGoogle Scholar
  14. 14.
    Clark GM. Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol Oncol. 2008;1(4):406-12.CrossRefGoogle Scholar
  15. 15.
    Wallace K, DeToma A, Lewin DN, et al. Racial differences in stage IV colorectal cancer survival in younger and older patients. Clin Colorectal Cancer. 2017;16(3):178–86.CrossRefGoogle Scholar
  16. 16.
    Shabihkhani M, Yu SS, Yang D, et al. Metastatic colorectal cancer in hispanics: treatment outcomes in a treated population. Clin Colorectal Cancer. 2016;15(4):e221–7.CrossRefGoogle Scholar
  17. 17.
    Shida D, Ahiko Y, Tanabe T, et al. Shorter survival in adolescent and young adult patients, compared to adult patients, with stage IV colorectal cancer in Japan. BMC Cancer. 2018;18(1):334.CrossRefGoogle Scholar
  18. 18.
    O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Do young colon cancer patients have worse outcomes? World J Surg. 2004;28(6):558–62.CrossRefGoogle Scholar
  19. 19.
    Azzoni C, Bottarelli L, Campanini N, et al. Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis. Int J Colorectal Dis. 2007;22(2):115–26.CrossRefGoogle Scholar
  20. 20.
    Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6.CrossRefGoogle Scholar
  21. 21.
    Watanabe T, Muro K, Ajioka Y, et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23(1):1–34.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Dai Shida
    • 1
    Email author
  • Taro Tanabe
    • 1
  • Narikazu Boku
    • 2
  • Atsuo Takashima
    • 2
  • Takefumi Yoshida
    • 1
  • Shunsuke Tsukamoto
    • 1
  • Yukihide Kanemitsu
    • 1
  1. 1.Department of Colorectal SurgeryNational Cancer Center HospitalTokyoJapan
  2. 2.Gastrointestinal Medical Oncology DivisionNational Cancer Center HospitalTokyoJapan

Personalised recommendations